Head-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, no pay-to-win placement.
One of the few names that actually holds a LegitScript certification you can look up — and pairs it with a genuinely rare oral GLP tablet — but the thin public site and some company-stated tiers keep the verdict honest.
Visit HealthRXA polished, high-disclosure compounded program with strong nationwide coverage.
Visit EdenEden takes it with a higher Verdict Score — 91/100 to 86/100 (grade A− vs B). People who prioritize a vetted, high-transparency provider over the lowest sticker price. HealthRX still earns its place — patients who want a verifiable, physician-supervised operator and would rather swallow a daily tablet than inject.
Neither of these is our overall #1. That title goes to CoreAge Rx (94/100) — the most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | HealthRX | Eden |
|---|---|---|
| Verdict Score | 86/100 | 91/100 |
| Grade | B | A− |
| Semaglutide | $189/mo | $239/mo |
| Tirzepatide | $349/mo | $349/mo |
| Coverage | Not publicly listed | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | No |
What we like
The caveats
What we like
The caveats
Also worth a look
Patients who want a verifiable, physician-supervised operator and would rather swallow a daily tablet than inject.
Visit HealthRX Read the full HealthRX review →Our pick — visit
People who prioritize a vetted, high-transparency provider over the lowest sticker price.
Visit Eden Read the full Eden review →Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.